Immune Modulating Peptide for the Suppression of Autoimmune Cells in Multiple Sclerosis

Abstract

Multiple Sclerosis is a chronic demyelinating inflammatory disease that causes symptoms ranging from fatigue to cerebellar ataxia. I propose a novel treatment for MS that targets the aberrant inflammatory cells directly in order to halt the progression of the disease. This protein complex will competitively bind to inflammatory cells that target the components of the central nervous system and subsequently eliminate them, thus eliminating the disease as it arises. Experimental autoimmune encephalomyelitis induced mice were treated with 0.2 mL of trimeric protein at peak disease. Gait score was used to measure disease progression. The cerebellum was fixed, sectioned and stained to measure lesion load. CD3+ and CD19+ cell populations from the spleens were counted. I found that administration of the trimeric protein at low doses significantly improved the motor function and significantly reduced the amount of cerebellar lesioned area of the EAE-induced mice.